- The TAP Study is an in-development project. 'TAP' stands for 'Treatment As Prevention' (of Hepatitis C).
- The logo will be used primarily for the purposes of promotion and dissemination of study findings. It will be used on the website of the study's coordinating organisation, the Burnet Institute (http://www.burnet.edu.au), and on dissemination products (e.g., PowerPoint presentations at conferences, the study's final report).
- The target audience will be key professional stakeholders in public health (e.g., government representatives, fellow researchers, staff of health services, such as hospitals).
Background to the TAP Study:
- Hepatitis C Virus is a major global cause of liver cirrhosis and cancer. Transmission occurs primarily through blood contact.
- In a number of developed countries, including Australia, injecting drugs with non-clean equipment is the most common form of Hepatitis C transmission.
- Unfortunately, there is no vaccine for the virus. In addition, current treatments are not 100% effective and are generally associated with numerous negative side-effects.
- However, research trials have demonstrated that a new drug can safely and effectively treat Hepatitis C.
- The TAP Study will investigate the feasibility of treating people who inject drugs with Hepatitis C using this new therapy. Treatment will be provided in community-based settings in Melbourne, Australia.
- The TAP Study will also examine whether treating people who inject drugs and their injecting networks (i.e., people they regularly inject with) will impact Hepatitis C transmission rates.